Dmitry I. Gabrilovich, MD, PhD
Amid growing evidence of their importance in the immune system, myeloid-derived suppressor cells (MDSCs) are gaining traction as a target for anticancer therapies, according to Dmitry I. Gabrilovich, MD, PhD, a leading expert in the field.
Combination Studies Underway
One budding area of research consists of combining agents that target MDSC activity with checkpoint immunotherapies.
... to read the full story